Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib in pediatric RET-altered tumors
NCT03899792Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
A Phase 2 trial of selpercatinib in Medullary Thyroid Cancer (MTC), papillary thyroid cancer (PTC), infantile myofibromatosis (IM), infantile fibrosarcoma (IFS), soft tissue sarcoma (STS), sponsored by Eli Lilly and Company. Started Jun 2019; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
Medullary Thyroid Cancer (MTC)papillary thyroid cancer (PTC)infantile myofibromatosis (IM)infantile fibrosarcoma (IFS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03899792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899792.